Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update which includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

• Publication year

  2022

• Venue

  Blood

• Publication date

  2022-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.2022016867PMID 35797463
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy

  2021cited by this paper
• European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia.

  2018cited by this paper

• Long-term effects of multidisciplinary team recommendations on adult patients with acute myeloid leukemia.

  2026cites this paper
• Safety profile of FLT3 inhibitors in acute myeloid leukemia: a systematic review and meta-analysis of adverse events

  2026cites this paper
• Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia

  2026cites this paper
• Clinico-genomic characterization of RAS-mutant acute myeloid leukemia

  2026influential citation
• Superior response and survival of intensive chemotherapy over venetoclax plus azacitidine in newly diagnosed KIT-mutated acute myeloid leukemia

  2026cites this paper
• Efficacy and safety of Venetoclax combined with Azacitidine in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation - a single-center retrospective study.

  2026cites this paper
• CEBPA‐bZIP Mutations in AML Patients Treated With Non‐Intensive Therapy: A Study by the Spanish PETHEMA Registry

  2026cites this paper
• Beyond XX and XY, Understanding Sex Differences in Leukemia

  2026cites this paper
• Navigating the Complexity of Newly Diagnosed AML Myelodysplasia-Related: A Case Report Highlighting Diagnostic Challenges and Therapeutic Dilemmas

  2026cites this paper
• Overcoming therapeutic challenges in acute myeloid leukemia: active targeting strategies by nano-drug delivery systems.

  2026cites this paper
• Increased IL4I1 expression predicts poor survival and modulates the immune microenvironment in acute myeloid leukemia

  2026cites this paper
• Prognostic impact of immunophenotypic classification for newly diagnosed NPM1-mutated acute myeloid leukemia.

  2026cites this paper
• Time to haematologist visit and non-haematological referral from primary health care during blood cancer diagnosis – findings from a large national survey in Australia

  2026cites this paper
• Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care.

  2026cites this paper
• Dominant TET2 mutations predict adverse prognosis in cytogenetically normal acute myeloid leukemia patients

  2026cites this paper
• Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions

  2026cites this paper
• Design, synthesis, formulation, and bioevaluation of ZZP-2, a FLT3-ITD inhibitor for the treatment of acute myeloid leukemia.

  2026cites this paper
• A Review of Pediatric Orthopedic Disorders: Diagnosis and Treatment Updates

  2026influential citation
• Maternal and Fetal Outcomes in Pregnant Women with Acute Leukemia

  2026cites this paper
• Treatment of Acute Myeloid Leukemia in Elderly Patients With Azacitidine-Venetoclax Combination in Developing Countries: A Single-Center Experience.

  2026cites this paper
• Dynamic changes in mortality risk factors for acute leukemia patients in the ICU and Post-ICU periods

  2026cites this paper
• Impact of venetoclax trough levels on safety and efficacy in the treatment of acute myeloid leukemia

  2026cites this paper
• Validating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation With Survival Outcomes and Comparison to ELN 2017.

  2026cites this paper
• Short-course high-dose cytarabine consolidation therapy before allogeneic hematopoietic stem cell transplantation improves 2-year relapse-free survival but not overall survival in patients with acute myeloid leukemia: a single-center retrospective study

  2026cites this paper
• Comprehensive geriatric assessment (CGA) scale does not effectively identify elderly AML patients suitable for intensive induction chemotherapy – a multicenter study from Polish Adult Leukemia Group

  2026cites this paper
• Differential Prognosis and Transplant Strategies in CBF-AML With RUNX1::RUNX1T1 Versus CBFβ::MYH11 Fusions.

  2026cites this paper
• Hypomethylating Agents and Venetoclax Based Triplets Targeting FLT3, IDH and KMT2A in Acute Myeloid Leukemia: Current Studies and Challenges of a Tailored Approach.

  2026cites this paper
• When remission alone might be good enough.

  2026cites this paper
• TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.

  2026cites this paper
• Management of Acute Myeloid Leukemia: A Review.

  2026cites this paper
• Unusual Presentation of Secondary Chronic Myeloid Leukemia in a Metastatic Breast Cancer Patient Receiving Cyclin-dependent Kinase 4/6 Inhibitor Therapy: A Case Report

  2026cites this paper
• Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML‐M4 and AML‐M5, Treated With Venetoclax Plus Azacitidine

  2026cites this paper
• Genetic landscape of pediatric acute myeloid leukemia in Taiwan

  2026cites this paper
• Refractory Clinical Course of Acute Myeloid Leukemia With t(8; 10; 21)(q22; q22; q22.1): A Case Report and Literature Review of This Variant Form

  2026cites this paper
• Integrative analysis of proteomics and metabolomics reveals amino acid metabolism disorder in adriamycin-resistant acute myeloid leukemia cells

  2026cites this paper
• Molecularly targeted therapy and immunotherapy in leukemias

  2026cites this paper
• Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study

  2026influential citation
• Prähabilitation vor einer allogenen Blutstammzelltransplantation bei hämatologischen Neoplasien

  2026cites this paper
• Vascular complications in NPM1-Mutated acute myeloid leukemia: clinical features and prognosis

  2026cites this paper
• Infectious events in fit patients with relapsed or refractory acute myeloid leukemia treated with azacitidine-venetoclax or intensive chemotherapy.

  2026cites this paper
• bZIP-Domain Variant Allele Frequency Helps to Refine Risk Stratification in CEBPA-Mutated AML

  2026cites this paper
• PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockade

  2026cites this paper
• Real-World Pharmacokinetic and Exposure–Response Characterization of Venetoclax in Chinese Patients with Hematological Malignancies

  2026cites this paper
• Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.

  2026cites this paper
• Hemocomponentes e segurança transfusional na leucemia mieloide aguda (LMA): Desfechos clínicos e implicações para a prática em hemocentros públicos

  2026cites this paper
• Outcomes of patients with R/R FLT3mut+ AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation.

  2026cites this paper
• Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.

  2026cites this paper
• Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.

  2026cites this paper
• Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy

  2026cites this paper
• Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

  2026cites this paper
• Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation

  2026cites this paper
• Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia.

  2026cites this paper
• Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia.

  2026cites this paper
• Clinical, genetic, and familial features of POT1 tumor predisposition syndrome

  2026cites this paper
• Measurable residual disease by multicolor flow cytometry in acute myeloid leukemia: A comparison of peripheral blood and bone marrow.

  2026cites this paper
• Evaluation of intracellular nucleotide pools in peripheral blood and bone marrow mononuclear cells and their association with frontline intensive chemotherapy response rates in AML patients

  2026cites this paper
• A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.

  2026cites this paper
• Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia.

  2026cites this paper
• Protective effects of morin and propolis against cytarabine-induced neurotoxicity: a multi-biomarker approach

  2026cites this paper
• Biomarkers and advances in AML-MRC: from bench to bedside

  2026cites this paper
• ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia.

  2026cites this paper
• Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML.

  2026cites this paper
• Low GOPC mRNA expression is a novel candidate associated with increased risk of acute myeloid leukemia

  2026cites this paper
• Venetoclax-based combination regimens for therapy-related myeloid neoplasms.

  2026cites this paper
• Integrative Bioinformatics Reveals Novel Molecular Mechanisms and Therapeutic Targets in Acute Myeloid Leukaemia

  2026cites this paper
• Halofuginone exerts broad-spectrum cytotoxic effects by regulating p-eIF2α-S100A8/A9-calcium signaling, inhibiting global protein synthesis, and reversing the resistance of idarubicin in acute myeloid leukemia

  2026cites this paper
• AML Disparities Across Racial Ancestry Groups: A Spotlight on the NPM1 Mutations

  2026cites this paper
• Myeloid sarcoma masquerading as central nervous system diffuse large b-cell lymphoma: a case report and literature review

  2026cites this paper
• Serum gamma-glutamyl transpeptidase/albumin ratio in patients with acute myeloid leukemia: a new perspective on prognostic assessment.

  2026cites this paper
• Optical genome mapping as a high-resolution tool for uncovering cytogenetic complex and cryptic alterations in a cohort of patients with MDS and AML

  2026influential citation
• Pre-therapeutic bone marrow-resident leukemic cells in acute myeloid leukemia exhibit a distinct dysregulated calcium signature and stem-like profile reflecting minimal residual disease precursors

  2026cites this paper
• Long Title: Challenges in handling allogeneic stem cell transplantation in randomized clinical trials.

  2026cites this paper
• Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial

  2026cites this paper
• Stain-free artificial intelligence-assisted light microscopy for the identification of leukocyte morphology change in presence of bacteria

  2026cites this paper
• Venetoclax combined with ML385 overcomes chemotherapy resistance in acute myeloid leukemia by modulating Nrf2/ARE-mediated oxidative stress

  2026cites this paper
• Integrating FLT3-ITD molecular features with clinical risk factors improves risk stratification in acute myeloid leukemia

  2026cites this paper
• Efficacy and safety of mini-cvd combined with venetoclax and azacitidine in philadelphia chromosome-negative acute leukemia of ambiguous lineage: a single-center retrospective study

  2026cites this paper
• Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort

  2026cites this paper
• Post-transplantation gilteritinib maintenance therapy and therapeutic drug monitoring in pediatric acute myeloid leukemia with FLT3–internal tandem duplication

  2026cites this paper
• KIT Mutant/Core binding factor-negative acute myeloid leukemia might be a complex subgroup with dismal prognosis: a single-center retrospective analysis

  2026cites this paper
• PRC2‐Related Epigenetic Age Acceleration in Acute Myeloid Leukemia with DNMT3A and IDH2 Mutations

  2026cites this paper
• Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in acute myeloid leukemia

  2026cites this paper
• Dendritic Cell Therapy to Improve Cancer Outcomes. Recent Insights: A Narrative Review

  2026cites this paper
• Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives

  2026cites this paper
• Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid

  2026cites this paper
• NPM1c⁺-driven lncRNA dysregulation in AML: Mechanisms, Controversies and translational roadblocks

  2026cites this paper
• Impact of Fusion Partners and Transplantation Benefit in Intensively Treated KMT2A-Rearranged Acute Myeloid Leukemia

  2026cites this paper
• Ultra-Sensitive Mutation Detection Technology in Myeloid Neoplasms: New Tools for Patient Monitoring

  2026cites this paper
• Immunophenotypic abnormality quantification refines multiparameter flow cytometry‐based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission

  2026cites this paper
• Challenging and Successful Therapy Decision-Making for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer – A Case Report and Experience-Driven Strategy

  2026cites this paper
• Impact of prior solid tumor on outcomes of hematopoietic stem cell transplantation for hematologic malignancies: a propensity score-matched study.

  2026cites this paper
• CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis.

  2026cites this paper
• HSCs/MPPs as cells of origin with altered differentiation hierarchy impairing immunomicroenvironment in PML::RARA and CBFα/β fusion AML.

  2026cites this paper
• Analysis of the Efficacy and Safety of Venetoclax Combined with Decitabine in the Treatment of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

  2026cites this paper
• From pathogenesis to management: therapy-related myeloid neoplasms in survivors of female-specific cancers

  2026cites this paper
• Discovery and optimization of Menin-MLL inhibitors targeting acute myeloid leukemia.

  2026cites this paper
• Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia

  2026cites this paper
• Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes.

  2026cites this paper
• The Analytical Performance and Inter-laboratory Standardization of Next-Generation Sequencing (NGS) Panels for Genetic Risk Stratification in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

  2026cites this paper
• Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemia.

  2026cites this paper